Trials / Not Yet Recruiting
Not Yet RecruitingNCT06182761
A Study of Sunvozertinib Combined With Anlotinib in Local Advanced or Metastatic Non-small Cell Lung Cancer
Efficacy and Safety of Sunvozertinib With Anlotinib in EGFR-TKIs Resistant EGFR-sensitive Mutated Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC): a Prospective, Single-arm, Phase II Trial
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 45 (estimated)
- Sponsor
- Shanghai Zhongshan Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study will evaluate the efficacy and safety of treatment with sunvozertinib in combination with Anlotinib in patients whose disease has progressed following first-line EGFR-TKIs treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sunvozertinib combination with Anlotinib | Sunvozertinib 300 mg once daily (QD) with Anlotinib 12mg once daily （QD in Day 1-14） ，21 days in one cycle. |
Timeline
- Start date
- 2024-01-01
- Primary completion
- 2026-01-01
- Completion
- 2028-07-01
- First posted
- 2023-12-27
- Last updated
- 2023-12-27
Source: ClinicalTrials.gov record NCT06182761. Inclusion in this directory is not an endorsement.